Gastrectomy versus stomach left in situ with Roux-en-Y reconstruction for the treatment of gastroparesis
- 1 Downloads
Gastroparesis is a debilitating functional disorder of the stomach marked by delayed gastric emptying in the absence of mechanical obstruction. Patients with severe, refractory symptoms may ultimately be managed with Roux-en-Y reconstruction; however, it is unclear whether the stomach should be left in situ, similar to a conventional gastric bypass, or resected as in gastrectomy.
All patients undergoing Roux-en-Y for the treatment of gastroparesis (GP) at our institution from September 2010 through March 2018 were retrospectively reviewed. Patients with prior gastric resection or whose primary operative indication was not gastroparesis were excluded from analysis.
Twenty-six patients underwent Roux-en-Y with stomach left in situ (RY-SIS) and twenty-seven patients underwent gastrectomy with Roux-en-Y reconstruction during the study period. The mean age was 49.7 years in the RY-SIS cohort and 48.5 years in the gastrectomy cohort. Etiology of GP was similar between the two cohorts. Patients undergoing gastrectomy were more likely to have previous interventions for GP (63.0% vs. 26.9%). RY-SIS was associated with a shorter operative time (155 vs. 223 min), less blood loss (24 vs. 130 mL), and shorter length of stay (4.0 vs. 7.2 days). Twelve patients (44.4%) had complications within 30 days following gastrectomy compared to two patients (7.7%) following RY-SIS (p = 0.001). Patients in the RY-SIS cohort were more likely to require further subsequent surgical intervention for GP (23.1% vs. 3.7%, p = 0.04). At last follow-up, there were no differences in reported GP symptoms or symptom scoring.
Gastrectomy was associated with greater perioperative morbidity compared to leaving the stomach in situ. Symptomatic improvement at intermediate follow-up was equivalent following either procedure. However, patients undergoing RY-SIS were more likely to require subsequent surgical intervention, suggesting that gastrectomy may be a more definitive operation for the management of medically refractory gastroparesis.
KeywordsGastroparesis Gastrectomy Roux-en-Y
Compliance with ethical standards
Matthew D. Kroh has no conflict of interest relevant to this publication. Outside of the scope of this work, he serves as a consultant for Levita Magnetics and Medtronic. He has received research funding from Cook. John H. Rodriguez has no conflict of interest relevant to this publication. Outside of the scope of this publication, he has received research funding from Pacira Pharmaceuticals and Intuitive Surgical. Joshua P. Landreneau, Andrew Strong, Kevin El-Hayek have no conflict of interest or financial ties to disclose.
- 4.Myint AS, Rieders B, Tashkandi M, Borum ML, Koh JM, Stephen S, Doman DB (2018) Current and emerging therapeutic options for gastroparesis. Gastroenterol Hepatol 14:639–645Google Scholar
- 7.Mancini SA, Angelo JL, Peckler Z, Philp FH, Farah KF (2015) Pyloroplasty for refractory gastroparesis. Am Surg 81:738–746Google Scholar
- 9.Rodriguez J, Strong AT, Haskins IN, Landreneau JP, Allemang MT, El-Hayek K, Villamere J, Tu C, Cline MS, Kroh M, Ponsky JL (2018) Per-oral pyloromyotomy (POP) for medically refractory gastroparesis: short term results from the first 100 patients at a high volume center. Ann Surg 268:421–430. https://doi.org/10.1097/SLA.0000000000002927 CrossRefGoogle Scholar
- 12.Abell TL, Camilleri M, Donohoe K, Hasler WL, Lin HC, Maurer AH, McCallum RW, Nowak T, Nusynowitz ML, Parkman HP, Shreve P, Szarka LA, Snape WJ, Ziessman HA, American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine (2008) Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol 103:753–763. https://doi.org/10.1111/j.1572-0241.2007.01636.x CrossRefGoogle Scholar
- 13.Revicki DA, Rentz AM, Dubois D, Kahrilas P, Stanghellini V, Talley NJ, Tack J (2004) Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res 13:833–844. https://doi.org/10.1023/B:QURE.0000021689.86296.e4 CrossRefGoogle Scholar